Scott Gottlieb Quotes
EpiPen is not unique. It falls into a category of old drugs, many of which should have long been subject to generic competition.
Gottlieb, Scott. "How the FDA Could Fix the EpiPen Crisis." Forbes, 26 Aug. 2016.
In 1989 the company that owned the only drug that was helpful in treating AIDS had not yet made it available for children:
In order to obtain the support for Obamacare from the Pharmaceutical industry, Obama, agreed to take this power away from the government.
Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.